InvestorsHub Logo
Followers 28
Posts 4308
Boards Moderated 1
Alias Born 09/22/2006

Re: maumar post# 4663

Wednesday, 08/10/2016 10:16:43 AM

Wednesday, August 10, 2016 10:16:43 AM

Post# of 8491
MAB SC conversion is currently 34% compared to 47% for Herceptin. However, MAB was just approved for another indication (leukemia) in Europe so it should continue to provide a decent increase in revenue in future Qs.

The chart in the sticky above was updated by the author to include the most recent Q. Steady upward movement is clearly indicated.
Good luck!
-Fritz

The more you know, the less you don't know.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News